MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering

Rhea-AI Summary

August 2024 Purdue/CME Ag Economy Barometer fell 13 points to 100, matching levels from fall 2015–winter 2016.

The Index of Current Conditions declined 17 points to 83, and the Index of Future Expectations dropped 11 points to 108. The Farm Financial Performance Index fell 9 points month-over-month and 14 points year-over-year to its lowest level since July 2020. The Farm Capital Investment Index hit an all-time low of 31. Concern over lower commodity prices rose to 30% of respondents, while 70% expect farmland cash rental rates for the 2025 crop year to remain stable.

Positive

• 70% of crop farmers expect 2025 rental rates to remain stable
• Long-Term Farmland Value Index remains elevated at 142

Negative

• Ag Economy Barometer down 13 points to 100 in August 2024
• Index of Current Conditions fell 17 points to 83
• Farm Financial Performance Index down 14 points YoY, lowest since July 2020
• Farm Capital Investment Index hit all-time low of 31

News Market Reaction

-0.96%

1 alert

-0.96% News Effect

On the day this news was published, CME declined 0.96%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Ag Economy Barometer: 100 Index of Current Conditions: 83 Index of Future Expectations: 108 +5 more

8 metrics

Ag Economy Barometer 100 August 2024 reading, down 13 points from July

Index of Current Conditions 83 August 2024, down 17 points from July

Index of Future Expectations 108 August 2024, down 11 points from July

Farm Capital Investment Index 31 August 2024, matches all-time low

Short-Term Farmland Value Index 105 August 2024, down 21 points year-over-year

Long-Term Farmland Value Index 142 August 2024, down 4 points from July

Concern: lower commodity prices 30% Share of respondents citing as primary concern

Expect lower interest rates 68% Respondents expecting interest rates to decrease in coming year

Market Reality Check

Price: $281.39 Vol: Volume 230,232 is 5.0x th...

high vol

$281.39 Last Close

Volume Volume 230,232 is 5.0x the 20-day average of 45,996, indicating unusually heavy trading ahead of/around this news. high

Technical Shares at $5.42 are trading below the 200-day MA of $8.99 and close to the 52-week low of $5.23.

Peers on Argus

MTVA fell 30.06% while closely ranked biotech peers showed mixed moves (e.g., LP...

MTVA fell 30.06% while closely ranked biotech peers showed mixed moves (e.g., LPCN +6.38%, PRTG -10.39%, THAR +4.79%, SYBX -5.04%). This divergence and lack of scanner momentum in peers point to a stock-specific reaction rather than a sector-wide biotech move.

Historical Context

5 past events · Latest: Jan 05 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 05	Clinical data update	Positive	-8.7%	Positive Phase 1b DA-1726 metabolic results with strong weight loss data.
Dec 29	Conference participation	Neutral	-2.1%	Announcement of participation and sponsorship of 10th Annual MASH-TAG 2026.
Dec 22	Listing compliance	Positive	+11.6%	Regained compliance with Nasdaq minimum bid price requirement.
Dec 02	Reverse stock split	Negative	-20.1%	1-for-11 reverse split to support Nasdaq continued listing compliance.
Nov 07	Clinical data update	Positive	+6.8%	Positive Phase 2a vanoglipel data in presumed MASH presented at AASLD.

Pattern Detected

Recent history shows frequent negative or muted reactions, including to positive clinical data, with only one clear positive alignment on a compliance update.

Recent Company History

Over the past six months, MetaVia has reported several key developments, including positive Phase 2a data for vanoglipel and positive Phase 1b results for DA-1726, yet the stock reaction was negative or modest on some of these updates. Corporate actions tied to Nasdaq compliance, such as the 1-for-11 reverse split on Dec 4, 2025 and a later notice of regaining minimum bid compliance on Dec 19, 2025, produced sharply negative and then positive moves. Today’s underwritten public offering headline arrives after this pattern of volatile responses to both clinical and corporate news.

Market Pulse Summary

This announcement of a $8.1 million underwritten public offering comes after a period marked by reve...

Analysis

This announcement of a $8.1 million underwritten public offering comes after a period marked by reverse splits, Nasdaq listing actions, and both positive and negatively received clinical updates. Investors may focus on how additional capital interacts with prior liquidity steps such as the $2.3 million at-the-market program and the Q3 2025 net loss of $3.38 million, as well as on continued progress for vanoglipel and DA‑1726.

Key Terms

ag economy barometer, index of current conditions, index of future expectations, farm financial performance index, +1 more

5 terms

ag economy barometer technical

"The August Purdue University/CME Group Ag Economy Barometer dropped 13 points"

A ag economy barometer is an index or composite measure that tracks the health of the agricultural sector by combining signals like crop and livestock prices, farm income, input costs and equipment or land sales into a single readout. Investors use it like a weather gauge for farming—rising readings suggest stronger commodity prices and agribusiness profits while falling readings warn of tighter margins, weaker rural demand and potential impacts on related stocks and loans.

index of current conditions technical

"The Index of Current Conditions also dropped 17 points to 83"

An index of current conditions is a single number that summarizes how healthy or active a part of the economy or a business sector is right now, usually based on surveys or real-time data like production, hiring, orders, or sales. Investors use it like a dashboard or a health check to see whether things are improving or worsening and to decide if they should buy, hold, or sell assets based on the likely short-term direction of markets.

index of future expectations technical

"while the Index of Future Expectations decreased by 11 points to 108"

An index of future expectations is a single-number measure, typically built from surveys or statistical models, that summarizes how consumers, businesses, or market participants expect economic or market conditions to change over the coming months. Investors treat it like a weather forecast for the economy: a rising index suggests improving conditions that could boost corporate profits and asset prices, while a falling index signals caution and higher risk of weaker returns.

farm financial performance index technical

"The Farm Financial Performance Index dropped 9 points from July's survey"

A composite metric that summarizes the financial health of farms or the agricultural sector by combining measures like revenues, costs, debt, cash flow and asset values into a single score. Like a dashboard gauge that shows whether a vehicle is running smoothly or needs attention, the index helps investors compare farms over time, assess risk and creditworthiness, and make informed decisions about agricultural stocks, loans or commodity exposure.

farm capital investment index technical

"resulting in the Farm Capital Investment Index falling 7 points to 31"

A farm capital investment index measures how much money is being spent on long‑lasting farm assets — such as tractors, buildings, irrigation systems and other infrastructure — over time. Investors use it like a thermometer for the agricultural sector: rising values suggest farmers are replacing or upgrading equipment and expanding capacity (which can boost future crop supply and efficiency), while falling values can signal underinvestment and potential production or productivity risks.

AI-generated analysis. Not financial advice.

CAMBRIDGE, Mass., Jan. 15, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA) (MetaVia or the Company), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the pricing of its underwritten public offering of shares of common stock (or common stock equivalents) and Series C Warrants and Series D Warrants for gross proceeds of approximately $8.1 million, prior to deducting underwriting discounts and commissions and offering expenses and excluding any potential future proceeds from the exercise of warrants.

The underwritten public offering is comprised of an aggregate of 2,613,544 shares of common stock (or common stock equivalents), 3,920,316 Series C Warrants and 3,920,316 Series D Warrants priced at a combined public offering price of $3.10 per share of common stock and accompanying Series C Warrants and Series D Warrants. The Series C Warrants are immediately exercisable, have an exercise price of $3.10, and expire on the five year anniversary of the initial issuance date. The Series D Warrants are immediately exercisable, have an exercise price of $3.10, and expire on the two year anniversary of the initial issuance date. The Series D Warrants are callable at the Company's option following the release of a positive data readout for its Phase 1b Part III clinical trial for DA-1726 via a widely disseminated press release, subject to satisfaction of certain conditions. The Series C Warrants and Series D Warrants issued in this offering are fixed priced and do not contain any variable pricing features or alternative exercise provisions.

Ladenburg Thalmann & Co. Inc. is acting as sole book-running manager in connection with the underwritten public offering.

If fully exercised for cash, the Pre-Funded Warrants, the Series C Common Warrants and the Series D Common Warrant could yield up to approximately an additional $24.0 million in future gross proceeds. MetaVia intends to use the net proceeds from the underwritten public offering for working capital and general corporate purposes, including to continue the clinical development of DA-1726 for the treatment of obesity.

In addition, MetaVia granted the underwriters a 45-day option to purchase up to an additional 392,030 shares of common stock, 588,045 Series C Warrants and 588,045 Series D Warrants, at the public offering price of $3.10 per share, less underwriting discounts and commissions.

This underwritten public offering is expected to close on or about January 16, 2026, subject to the satisfaction of customary closing conditions.

The securities issued as part of the underwritten public offering were offered pursuant to a registration statement on Form S-1 (File No. 333-292581), which was initially filed with the U.S. Securities and Exchange Commission ("SEC") on January 5, 2026, as amended on January 12, 2026, and declared effective on January 15, 2026 and an additional registration statement on Form S-1 filed pursuant to Rule 462(b), which was filed on January 15, 2026 and became effective upon filing.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The underwritten public offering is being made solely by means of a prospectus. A final prospectus relating to this underwritten public offering will be filed by MetaVia with the SEC. When available, copies of the final prospectus can be obtained at the SEC's website at www.sec.gov or from Ladenburg Thalmann & Co. Inc., Prospectus Department, 640 Fifth Avenue, 4th Floor, New York, New York 10019 or by email at prospectus@ladenburg.com.

 About MetaVia

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing vanoglipel (DA-1241) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. Vanoglipel (DA-1241) is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, vanoglipel (DA-1241) demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, vanoglipel (DA-1241) demonstrated direct hepatic action in addition to its glucose lowering effects.

For more information, please visit www.metaviatx.com.

Forward Looking Statements

Certain statements in this press release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believes", "expects", "anticipates", "may", "will", "should", "seeks", "approximately", "potential", "intends", "projects", "plans", "estimates" or the negative of these words or other comparable terminology (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements, which include, among other statements, statements regarding the anticipated use of the net proceeds from the underwritten public offering, the potential future gross proceeds from the underwritten public offering, and the expected closing date of the underwritten public offering. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including, without limitation, those risks associated with MetaVia's ability to execute on its commercial strategy; MetaVia's expectations regarding the sufficiency of its existing cash on hand to fund MetaVia's operations; the timeline for regulatory submissions; the ability to obtain regulatory approval through the development steps of MetaVia's current and future product candidates; the ability to realize the benefits of the license agreement with Dong-A ST Co. Ltd., including the impact on future financial and operating results of MetaVia; the cooperation of MetaVia's contract manufacturers, clinical study partners and others involved in the development of MetaVia's current and future product candidates; potential negative interactions between MetaVia's product candidates and any other products with which they are combined for treatment; MetaVia's ability to initiate and complete clinical trials on a timely basis; MetaVia's ability to recruit subjects for its clinical trials; whether MetaVia receives results from MetaVia's clinical trials that are consistent with the results of pre-clinical and previous clinical trials; impact of costs related to the license agreement, known and unknown, including costs of any litigation or regulatory actions relating to the license agreement; the effects of changes in applicable laws or regulations; the effects of changes to MetaVia's stock price on the terms of the license agreement and any future fundraising; and other risks and uncertainties described in MetaVia's filings with the Securities and Exchange Commission, including MetaVia's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date when made. MetaVia does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contacts:

MetaVia
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@metaviatx.com

Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com 

FAQ

What was the August 2024 Purdue/CME Ag Economy Barometer reading?

The barometer fell 13 points to a reading of 100 in August 2024.

How did farmers' view of current conditions change in August 2024?

The Index of Current Conditions dropped 17 points to 83, indicating weaker sentiment.

What does the August 2024 survey say about farm financial performance?

The Farm Financial Performance Index fell 9 points month-over-month and 14 points year-over-year to its lowest level since July 2020.

How did farmers' expectations for farmland values shift in August 2024?

Short-term farmland expectations fell 13 points to 105, with the share expecting declines rising to 24%.

What percentage of farmers cited lower commodity prices as their primary concern in August 2024?

30% of respondents named lower commodity prices as their top concern in August 2024.